Cellectis (NASDAQ:CLLS) Issues Earnings Results

Cellectis (NASDAQ:CLLS) posted its quarterly earnings data on Monday. The biotechnology company reported ($0.64) EPS for the quarter, reports. Cellectis had a negative return on equity of 73.03% and a negative net margin of 346.65%. The company had revenue of $1.99 million for the quarter.

Cellectis Trading Down 0.9 %

Shares of CLLS opened at $2.54 on Thursday. Cellectis has a 52-week low of $0.96 and a 52-week high of $3.77. The business’s fifty day moving average is $2.61 and its 200-day moving average is $2.67. The company has a current ratio of 2.20, a quick ratio of 2.20 and a debt-to-equity ratio of 0.57.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on Cellectis in a research note on Saturday, April 27th. They set a “sell” rating on the stock.

Hedge Funds Weigh In On Cellectis

An institutional investor recently raised its position in Cellectis stock. Baillie Gifford & Co. grew its holdings in Cellectis S.A. (NASDAQ:CLLS) by 1.3% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 827,248 shares of the biotechnology company’s stock after purchasing an additional 10,605 shares during the period. Baillie Gifford & Co. owned approximately 1.49% of Cellectis worth $2,192,000 as of its most recent SEC filing. Institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.